Helicobacter pylori Antimicrobial Susceptibility Testing-Guided Eradication Therapy in the Southeast Region of China: A Retrospective Study
Dan Ma,Yunhui Fang,ZiWei Wang,Mosang Yu,Xin Xin Zhou
DOI: https://doi.org/10.2147/idr.s487503
2024-11-23
Infection and Drug Resistance
Abstract:Dan Ma, 1, &ast Yunhui Fang, 2, &ast ZiWei Wang, 1 Mosang Yu, 1 Xin Xin Zhou 1 1 Department of Gastroenterology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou City, People's Republic of China; 2 State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou City, People's Republic of China &astThese authors contributed equally to this work Correspondence: Xin Xin Zhou, Department of Gastroenterology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou City, 310003, People's Republic of China, Email Background and Aim: Antibiotic resistance of Helicobacter pylori is increasing worldwide, lowering its efficacy in eradication therapy and posing a serious threat to human health. This study evaluated H. pylori resistance to antibiotics in the southeast region of China and explored factors related to eradication failure guided by antimicrobial susceptibility testing (AST). Methods: In this retrospective study, patients who tested positive underwent gastroscopy, and H. pylori infection was confirmed by histological staining and H. pylori culture. We determined the rate of H. pylori antibiotic resistance, success rate of AST-guided eradication therapy, and risk factors associated with treatment failure. Results: Among the 210 enrolled patients, 188 (89.5%) had successful cultures, and 183 (87.1%) underwent AST. The most common antibiotic resistance was to metronidazole and clarithromycin (89.6%), followed by levofloxacin (68.3%), and amoxicillin (14.2%). Furazolidone (3.0%) and tetracycline (0.5%) showed relatively low resistance rates. There were no statistically significant differences in the rates of resistance to MET, LEV, or AMX between naive and non-naive patients. However, CLA resistance rates in non-naive patients were significantly higher than those in naive patients. The overall success rate of AST-guided therapy was high and showed no significant difference between first-line and rescue therapy. Sex, age, prior therapy, and proton pump inhibitors (PPIs) or potassium-competitive acid blockers (P-CABs) use were not significantly associated with an increased risk of eradication failure in AST-guided therapy. Keywords: Antibiotic resistance, Culture, Helicobacter pylori , Eradication therapy. Helicobacter pylori (H. pylori) is a globally prevalent pathogen that colonizes the stomach. Persistent infection may lead to various gastrointestinal diseases including chronic gastritis, peptic ulcer, gastric cancer, and MALT lymphoma. 1,2 Its prevalence is significantly higher in developing countries than in developed countries. 3 Therefore, the eradication of H. pylori is a promising method to prevent gastric cancer in a cost-effective manner. Unfortunately, the eradication rate has been decreasing owing to the emergence of antibiotic resistance strains. 4 Antibiotic resistance has reached alarming levels worldwide, especially nitroimidazole, clarithromycin and levofloxacin resistance. The pooled prevalence of primary resistance ranged from 21% to 37% for clarithromycin, 51% to 83% for metronidazole, and 18% to 42% for levofloxacin in recent 10 years. 5 It is characterized by the involvement of diverse mechanisms, including mutagenic modifications in drug target sites, membrane permeability variations, biofilm formation, and an abundance of efflux pump systems. 6 Thus, the prevalence of antibiotic resistance makes it more difficult for traditional empirical therapy to successfully eradicate H. pylori . Recent reports show that antimicrobial susceptibility testing (AST)-guided treatment improves the bacterial eradication rates. 7,8 H. pylori AST is performed by culturing bacteria from gastric biopsies during endoscopic examination and determining the minimum inhibitory concentration of antibiotics required to inhibit bacterial growth. 9 Current guidelines recommend that patients who fail more than one course of H. pylori treatment undergo culture and AST to select susceptible antibiotics for tailored therapy. 10 Hence, drug susceptibility testing of H. pylori is crucial for successful eradication therapy. Recent studies have shown a relatively lower success rate (around 90%) in H. pylori cultures compared to UBT, -Abstract Truncated-
pharmacology & pharmacy,infectious diseases